SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gets EIR from USFDA for Patalganga manufacturing facility

20 Jan 2020 Evaluate

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for Patalganga manufacturing facility. The Company has received the EIR, indicating closure of the inspection. USFDA had conducted inspection at Patalganga manufacturing facility from November 4, 2019 to November 13, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1356.30 22.75 (1.71%)
06-May-2026 11:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1841.00
Dr. Reddys Lab 1295.60
Cipla 1356.30
Zydus Lifesciences 934.20
Lupin 2417.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×